HMHitoshi Minamiguchi

Hitoshi Minamiguchi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hitoshi Minamiguchi has a total of 232 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Time Interval Between Arrhythmia Detection and Clinical Diagnosis in Patients With Implantable Loop Recorders ― A Single-Center Experience With Current In-Office Follow-up Strategy ―

    by Takashige Sakio, Hitoshi Minamiguchi, Yasuhiro Ichibori, Kei Nakamoto, Naoki Mori, Takashi Kanda, Mikiko Matsumura, Yuki Shibuya, Takuma Kanayama, Takashi Hyogo, et al.

    Background: Implantable loop recorders (ILRs) are essential for diagnosing unexplained syncope and embolic stroke of undetermined source (ESUS). However, the timing of clinical diagnosis often depends on the follow-up model. This study aimed to quantify the “diagnostic gap” (i.e., the interval between arrhythmia onset and clinical recognition) in a conventional in-office follow-up setting in Japan.Methods and Results: We retrospectively analyzed 143 consecutive patients who underwent ILR implantation. Actionable arrhythmias were detected in 45 patients (31%). Except for 2 patients in whom arrhythmia events were detected during hospitalization, 43 patients were divided into 2 groups: an “unscheduled” group (n=8), who sought urgent care due to symptoms, and a “scheduled” group (n=35), whose arrhythmias were discovered during routine office visits. Although the median diagnostic gap in the unscheduled group was 0 days, the scheduled group experienced a median gap of 25 days (interquartile range: 4–75 days). Approximately 80% of clinical interventions were delayed until a scheduled appointment, despite the device having recorded the event much earlier.Conclusions: In a conventional in-office follow-up model, a significant diagnostic lag existed for the majority of ILR patients, particularly for those with asymptomatic events. To maximize the clinical benefit of ILR and ensure timely therapeutic intervention, our findings support the potential role of remote monitoring in reducing this gap.

  • Particles of Drug-Coated Balloons Captured by Flow Reversal Method

    by Daichi Yoshii, Osamu Iida, Masahiko Fujihara, Takuya Tsujimura, Taku Toyoshima, Yoshiteru Okina, Hitoshi Minamiguchi, Yasuhiro Ichibori, Kei Nakamoto, Naoki Mori

  • Open Access

    Differential Impact of Low Voltage Area Radiofrequency Ablation on Recurrence of Atrial Fibrillation Versus Atrial Tachycardia in Patients With Persistent Atrial Fibrillation

    by Daisuke Sakamoto, Akihiro Sunaga, Yuki Matsuoka, Hideaki Hasegawa, Hirota Kida, Tomoharu Dohi, Daisaku Nakatani, Katsuki Okada, Tetsuhisa Kitamura, Masaharu Masuda, et al.


  • Open Access

    Win ratio analysis of low-voltage area ablation in persistent atrial fibrillation: sub-analysis of SUPPRESS-AF

    by Akihiro Sunaga, Yuki Matsuoka, Daisaku Nakatani, Katsuki Okada, Daisuke Sakamoto, Hideaki Hasegawa, Tetsuhisa Kitamura, Masaharu Masuda, Nobuaki Tanaka, Tetsuya Watanabe, et al.

    Aims: In persistent atrial fibrillation (AF), low-voltage areas (LVAs) in the left atrium are considered arrhythmogenic. Although substrate ablation targeting LVAs may reduce AF recurrence, its effect on broader clinical outcomes remains unclear, and procedural risks must be considered. This study aims to compare hierarchical clinical outcomes between pulmonary vein isolation (PVI) alone and PVI plus LVA ablation in patients with persistent AF and LVAs using a win ratio analysis. Methods and results: This was a post hoc sub-analysis of the SUPPRESS-AF trial, including 341 patients with LVAs out of 1364 randomized. Patients received either PVI alone (n = 171) or PVI with LVA ablation (n = 170). Hierarchical outcomes were analysed in order of clinical importance: all-cause death, symptomatic stroke, AF recurrence, bleeding, and periprocedural complications. Win ratio analysis was used for comparison. Baseline characteristics were balanced between groups. The PVI plus LVA group had longer procedure times and higher energy delivery. The win ratio analysis showed no significant difference between groups (win ratio: 1.01, 95% confidence interval: 0.73–1.39, P = 0.940). The PVI-alone group had numerically fewer adverse events, while the LVA ablation group showed a numerical reduction in AF recurrence. Subgroup analyses showed consistent findings. Conclusion: In patients with persistent AF and LVAs, LVA ablation added to PVI did not improve hierarchical clinical outcomes and prolonged procedures. Routine use of current LVA ablation strategies is not supported, though targeted substrate modification may warrant further research. Registration: UMIN-CTR, https://www.umin.ac.jp/ctry. UMIN000035940.


  • Catheter Ablation Outcomes and Life Expectancy in Very Elderly Atrial Fibrillation Patients

    by Shu Hirata, Yasuo Okumura, Koichi Nagashima, Ryuta Watanabe, Katsuaki Yokoyama, Naoya Matsumoto, Takeshi Kato, Hidehira Fukaya, Hidemori Hayashi, Shiro Nakahara, et al.


  • Open Access

    Efficacy of Low-Voltage-Area Ablation Is Enhanced in Patients With Advanced Left Atrial Enlargement: A Subanalysis of the SUPPRESS-AF Trial

    by Masaharu Masuda, Yasuhiro Matsuda, Hiroyuki Uematsu, Hirotaka Ooka, Satoshi Kudo, Mizuki Ochi, Toshiaki Mano, Akihiro Sunaga, Nobuaki Tanaka, Tetsuya Watanabe, et al.

    BACKGROUND: In the randomized controlled SUPPRESS-AF trial (Efficacy and Safety of Left Atrial Low-voltage Area Guided Ablation for Recurrence Prevention Compared to Pulmonary Vein Isolation Alone in Patients with Persistent Atrial Fibrillation), the efficacy of low-voltage-area (LVA) ablation was highly dependent on the degree of atrial remodeling, while the efficacy was not statistically significant in total patients. This subanalysis of the SUPPRESS-AF trial aimed to compare the efficacy of LVA ablation in patient groups classified by left atrial diameter (LAD), which is a commonly used atrial remodeling index. METHODS: The SUPPRESS-AF trial included patients with persistent AF and left atrial LVAs, and compared rhythm outcomes between patients randomized to undergo pulmonary vein isolation (PVI) followed by left atrial LVA ablation group (n=170) or PVI-alone group (n=172). In this post hoc subanalysis, patients in each of the 2 randomly allocated groups were further divided into 2 groups using a median LAD of 44 mm. RESULTS: Atrial fibrillation or atrial tachycardia recurrence–free rates did not differ between patients with LAD>44 mm and ≤44 mm (60.1% versus 53.7%; P =0.261). Among patients with a LAD>44 mm, the LVA ablation group demonstrated a higher atrial fibrillation or atrial tachycardia-recurrence–free rate than the PVI-alone group (62.5% versus 43.4%; P =0.016). In contrast, no difference in atrial fibrillation or atrial tachycardia recurrence–free rate was found between the 2 groups of patients with a LAD≤44 mm (60.8% versus 59.6%; P =0.986). CONCLUSIONS: The efficacy of LVA ablation in addition to PVI for the treatment of persistent AF was more pronounced in patients with a large left atrium. REGISTRATION: URL: https://www.umin.ac.jp/ctr ; Unique identifier: UMIN000035940.


  • Open Access

    Successful retrieval of a detached metallic tip of a tissue stabilization sheath during a transvenous lead extraction: A case report

    by Naoki Mori, Hitoshi Minamiguchi, Takashi Kanda, Osamu Iida, Yoshiharu Higuchi


  • Open Access

    Impact of renal function on the efficacy of low-voltage area ablation after pulmonary vein isolation: a sub-analysis of the SUPPRESS-AF trial

    by Yasuhiro Matsuda, Masaharu Masuda, Toshiaki Mano, Takuya Tsujimura, Hiroyuki Uematsu, Hirotaka Ooka, Satoshi Kudo, Mizuki Ochi, Shin Okamoto, Takayuki Ishihara, et al.

    Aims: The SUPPRESS-AF trial showed that pulmonary vein isolation (PVI) plus low-voltage area (LVA) ablation may reduce atrial fibrillation (AF) recurrence in some subgroups. Renal dysfunction is a cause of LVAs due to atrial cardiomyopathy and is also a risk factor for AF recurrence after catheter ablation. The aim of this study was to investigate the efficacy of LVA ablation after PVI stratified by renal function. Methods and results: This study was a sub-analysis of the SUPPRESS-AF trial, a multicentre, prospective, randomized, open-label trial. A total of 341 consecutive patients who underwent initial radiofrequency catheter ablation for persistent AF and whose LVAs were ≥5 cm2 were analysed. Patients were randomized to PVI alone (PVI-alone group) or LVA ablation after PVI [PVI + LVA-ablation (ABL) group]. Primary outcome was defined as the recurrence of atrial tachyarrhythmias during the 12 months following ablation. Estimated glomerular filtration rate (eGFR) was assessed before ablation, and patients were stratified by chronic kidney disease (CKD) stage. The mean eGFR was 60 ± 16 mL/min/1.73 m2, and 146 (43%) patients developed the primary outcome. In patients with CKD G1-2 (eGFR ≥ 60 mL/min/1.73 m2), freedom from the primary outcome was similar between the PVI + LVA-ABL and PVI-alone groups (53.1% vs. 55.3%, P = 0.59). In contrast, in patients with CKD G3a-5 (eGFR < 60 mL/min/1.73 m2), freedom from the primary outcome was significantly higher in the PVI + LVA-ABL group than in the PVI-alone group (69.1% vs. 43.3%; P = 0.004). Conclusion: In patients with renal dysfunction, LVA ablation after PVI reduced AF recurrence after radiofrequency catheter ablation for persistent AF.

  • Impact of Initial Extensive Ablation on Left Atrial Gaps During Redo Procedures and Subsequent Outcomes in Persistent Atrial Fibrillation

    by Masato Okada, Koichi Inoue, Nobuaki Tanaka, Masaharu Masuda, Tetsuya Watanabe, Nobuhiko Makino, Yasuyuki Egami, Takafumi Oka, Hitoshi Minamiguchi, Miwa Miyoshi, et al.

    BACKGROUND: The efficacy of extensive linear ablation strategies, in addition to pulmonary vein (PV) isolation, remains controversial in persistent atrial fibrillation (AF) ablation. Gaps in previously ablated lesions can induce arrhythmias and potentially decrease the effectiveness of extensive ablation. This study evaluated the incidence of conduction gaps, gap-related reentry, and subsequent recurrence following redo AF ablation in the EARNEST-PVI trial (Efficacy of Pulmonary Vein Isolation Alone in Patients With Persistent Atrial Fibrillation; REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03514693 ). METHODS: The EARNEST-PVI trial is a randomized controlled study evaluating index ablation strategies for persistent AF. Of the 512 trial participants, 115 who underwent redo AF ablation (pulmonary vein isolation [PVI]-alone redo [n=69] and PVI-plus linear redo [n=46]) were included in the present study. Left atrial conduction gaps, the occurrence of left atrial tachycardias during redo procedures, and subsequent recurrences were compared between the PVI-alone redo group and the PVI-plus linear ablation redo group. RESULTS: In the PVI-alone redo group, electrical PV gaps were observed in 38 (57%) patients. In the PVI-plus redo group, 19 (41%) had PV gaps, 10 (22%) had gaps in left atrial linear lines, and 11 (24%) had gaps in both. During the redo session, 19 left atrial tachycardias were observed or induced in 15 patients. Atrial tachycardias were more frequently observed in the PVI-plus group than in the PVI-alone group (23.9% versus 5.8%; P =0.005). The occurrence of left atrial tachycardias was associated with gaps in linear lesions, whereas PV gaps alone were associated with subsequent recurrence after redo (hazard ratio, 0.54 [95% CI, 0.31–0.95]; P =0.033). CONCLUSIONS: In the redo AF ablation of the EARNEST-PVI trial, left atrial conduction gaps were more frequent in patients who underwent extensive linear ablation during the index procedure. While all gaps during redo were potentially arrhythmogenic, PV gaps alone were associated with recurrence after redo AF ablation. REGISTRATION: URL: https://www.umin.ac.jp/ctr/index-j.htm ; Unique identifier: UMIN000019449.


  • Top Cited Papers
    Open Access

    Low-voltage-area ablation for persistent atrial fibrillation: a randomized controlled trial

    by Masaharu Masuda, Akihiro Sunaga, Nobuaki Tanaka, Tetsuya Watanabe, Hitoshi Minamiguchi, Yasuyuki Egami, Takafumi Oka, Tomoko Minamisaka, Takashi Kanda, Masato Okada, et al.

    Low-voltage areas (LVAs) in the left atrium may promote atrial fibrillation (AF), but the efficacy of LVA ablation for preventing arrhythmia has not been determined. In the present study, we carried out a multicenter, randomized controlled trial (SUPPRESS-AF) to investigate the efficacy of LVA ablation in patients with persistent AF who had left atrial LVAs. Patients with persistent AF and left atrial LVAs that covered ≥5 cm2 of the left atrial surface on a voltage map after pulmonary vein isolation (PVI) were randomized to undergo LVA ablation (PVI + LVA-ABL group) or not (PVI-alone group) in a 1:1 fashion. Recurrence of AF or atrial tachycardia (AT) was monitored using 24-h Holter electrocardiography (ECG) and twice-daily portable ECG recordings. The primary endpoint was freedom from AF or AT recurrence without antiarrhythmic drug use during 1 year of follow-up. Of 1,347 patients (1,003 males and 344 females) who underwent initial ablation for AF, patients with left atrial LVAs were assigned to the PVI + LVA-ABL (n = 170) or the PVI-alone group (n = 171). Although the PVI + LVA-ABL group demonstrated a numerically higher rate of freedom from AF or AT recurrence compared with the PVI-alone group (61% (95% confidence interval (CI) = 53–68%) versus 50% (95% CI = 42–57%)), this difference did not reach statistical significance (P for log(rank) test = 0.127). There was no difference in the procedure-related serious adverse events between the two groups (1.7% versus 1.8%, P < 0.0001). In conclusion, LVA ablation in addition to PVI did not significantly reduce 1-year AF or AT recurrence in patients with persistent AF with left atrial LVAs. Future studies are needed to identify patients who may receive greater benefit from LVA ablation.